Provided by Tiger Fintech (Singapore) Pte. Ltd.

NEWAMSTERDAM PHARMA CO NV

19.75
-0.4600-2.28%
Pre-market: 19.850.1000+0.51%08:36 EDT
Volume:2.46M
Turnover:48.00M
Market Cap:2.22B
PE:-10.68
High:20.40
Open:20.21
Low:18.60
Close:20.21
Loading ...

NewAmsterdam Pharma files $500M mixed securities shelf

TIPRANKS
·
01 Mar

Analysts Offer Insights on Healthcare Companies: NewAmsterdam Pharma Company (NAMS) and Organogenesis Holdings (ORGO)

TIPRANKS
·
28 Feb

NewAmsterdam Pharma Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.
·
27 Feb

NewAmsterdam Pharma Is Maintained at Buy by Needham

Dow Jones
·
27 Feb

Newamsterdam Pharma Faces Potential Investor Risks Due to Shareholder Influence

TIPRANKS
·
27 Feb

NewAmsterdam Pharma Company (NAMS) Receives a Buy from William Blair

TIPRANKS
·
27 Feb

NewAmsterdam Pharma's Full-Year Net Loss Widens, Revenue Rises

MT Newswires Live
·
26 Feb

Earnings Flash (NAMS) NewAmsterdam Pharma Posts Full Year 2024 Revenue $45.6M, vs. FactSet Est of $33.8M

MT Newswires Live
·
26 Feb

Earnings Flash (NAMS) NewAmsterdam Pharma Posts Full Year 2024 Net Loss of $241.6M

MT Newswires Live
·
26 Feb

NewAmsterdam Pharma FY24 Sales $45.6M Beats $31.982M Estimate

Benzinga
·
26 Feb

Press Release: NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update

Dow Jones
·
26 Feb

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March

GlobeNewswire
·
25 Feb

Both private equity firms who control a good portion of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) along with institutions must be dismayed after last week's 8.1% decrease

Simply Wall St.
·
14 Feb

Newamsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
08 Feb

Novartis Edges Higher On Sales Beat As Competition Looms For Its Biggest Moneymaker

Blockhead
·
31 Jan

NewAmsterdam Pharma to Present at Guggenheim’s SMID Cap Biotech Conference

GlobeNewswire
·
29 Jan

NewAmsterdam Pharma Price Target Maintained With a $40.00/Share by RBC Capital

Dow Jones
·
28 Jan

RBC Capital Sticks to Their Buy Rating for NewAmsterdam Pharma Company (NAMS)

TIPRANKS
·
28 Jan

NewAmsterdam Pharma Price Target Maintained With a $40.00/Share by RBC Capital

Dow Jones
·
25 Jan

RBC Capital Sticks to Their Buy Rating for NewAmsterdam Pharma Company (NAMS)

TIPRANKS
·
24 Jan